Navigation Links
Lung Disease-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lung Disease-Pipeline Insights, 2014

http://www.reportlinker.com/p02278634/-Lung-Disease-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Lung Disease-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lung Disease. This report provides information on the therapeutic development based on the Lung Disease dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Lung Disease
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lung Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lung Disease and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Lung Disease
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Lung Disease pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Lung Disease Overview
- Lung Disease Pipeline Therapeutics

- Lung Disease Therapeutics under Development by Companies
- Lung Disease Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Lung Disease Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Lung Disease Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Lung Disease Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lung Disease – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lung Disease – Discontinued Products
- Lung Disease – Dormant Products
- Companies Involved in Therapeutics Development for Lung Disease
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Lung Disease, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Lung Disease Assessment by Monotherapy Products
- Lung Disease Assessment by Combination Products
- Lung Disease Assessment by Route of Administration
- Lung Disease Assessment by Stage and Route of Administration
- Lung Disease Assessment by Molecule Type
- Lung Disease Assessment by Stage and Molecule Type
- Lung Disease Therapeutics – Discontinued Products
- Lung Disease Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Lung Disease, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Lung Disease Assessment by Monotherapy Products
- Lung Disease Assessment by Combination Products
- Lung Disease Assessment by Route of Administration
- Lung Disease Assessment by Stage and Route of Administration
- Lung Disease Assessment by Molecule Type
- Lung Disease Assessment by Stage and Molecule Type

To order this report: Lung Disease-Pipeline Insights, 2014
http://www.reportlinker.com/p02278634/-Lung-Disease-Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Adenocarcinoma-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... 2014. Each year, reproductive endocrinologists are required to report in vitro fertilization ... of professionals dedicated to the practice of assisted reproductive technologies in the United ...
Breaking Medicine News(10 mins):